SEC 13F Intelligence

Managers / Q2 2023 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
Under review
reported total failed a data-quality check
Positions
54
Filings on Record
39
2019–present window
Filed
Aug 8, 2023
original filing

Summary

Compared with Q1 2023, the fund opened 1 new position and exited 2.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.9%Other: 17.1%
  • Common Stock · 82.9% · $111M
  • Other · 17.1% · $23M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
AXGNAXOGEN INCNEW+40.0K40.0K+$365,200$365,200
STOKSTOKE THERAPEUTICS INCADDED+70.0K85.0K+$903,425$903,550
SILKUSDSILK ROAD MEDICAL INCADDED+10.0K20.0K+$649,409$649,800
ANGION BIOMEDICA CORPSOLD OUT−54.4K0−$32$0
ASPIRA WOMEN'S HEALTH INCSOLD OUT−60.1K0−$22$0
NKTREURNEKTAR THERAPEUTICSTRIMMED−90.0K28.0K+$16,023$16,106
TVTXTRAVERE THERAPEUTICS INCADDED+10.0K40.0K+$613,725$614,400
INFLARX NVTRIMMED−20.0K50.0K+$222,864$223,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM34.92%$47M728.6K
2PROTHENA CORP PLCSHS7.99%$11M156.1K
3NBIXNEUROCRINE BIOSCIENCES INChistory →COM5.95%$8M84.2K
4BIODESIX INCCOM4.65%$6M5.04M
5ACADACADIA PHARMACEUTICALS INChistory →COM4.48%$6M249.4K
6QDEL*QUIDELORTHO CORPhistory →COM4.05%$5M65.2K
7ELUTAZIYO BIOLOGICS INChistory →COM2.93%$4M1.66M
8IMGNEURIMMUNOGEN INChistory →COM2.69%$4M190.0K
9UTHUNITED THERAPEUTICS CORPhistory →COM2.48%$3M15.0K
10OVVOVINTIV INChistory →COM2.40%$3M84.2K
11HROWHARROW HEALTH INChistory →COM2.14%$3M150.0K
12PHRPHREESIA INChistory →COM1.92%$3M82.7K
13MASI*MASIMO CORPhistory →COM1.88%$3M15.3K
14FHTXFOGHORN THERAPEUTICS INChistory →COM1.40%$2M264.8K
15INBXUSDINHIBRX INChistory →COM1.37%$2M70.4K
16ACCELERATE DIAGNOSTICS INCCOM1.37%$2M2.25M
17ALKERMES PLCSHS1.17%$2M50.0K
18ATECALPHATEC HOLDINGS INChistory →COM1.08%$1M80.0K
19ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.95%$1M133.1K
20HTDCORCEPT THERAPEUTICS INCCOM0.83%$1M50.0K
21APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.82%$1M12.0K
22SOLENO THERAPEUTICS INCCOM0.79%$1M245.1K
23PTGXPROTAGONIST THERAPEUTICS INCCOM0.79%$1M38.0K
24DCGODOCGO INCCOM0.77%$1M110.0K
25OPHTEURIVERIC BIO INCCOM0.74%$983,50025.0K
26STOKSTOKE THERAPEUTICS INCCOM0.68%$903,55085.0K
27VTYXUSDVENTYX BIOSCIENCES INCCOM0.65%$865,92026.4K
28BLUEBIRD BIO INCCOM0.61%$819,868249.2K
29CYTKCYTOKINETICS INCCOM0.61%$815,50025.0K
30PXDEURPIONEER NATURAL RESOURCES COCOM0.59%$787,2843.8K
31TXG10X GENOMICS INCCL A COM0.50%$670,08012.0K
32SILKUSDSILK ROAD MEDICAL INCCOM0.49%$649,80020.0K
33TVTXTRAVERE THERAPEUTICS INCCOM0.46%$614,40040.0K
34TSVT*2SEVENTY BIO INCCOM0.45%$605,51059.8K
35CHINOOK THERAPEUTICS INCCOM0.43%$576,30015.0K
36KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.39%$521,484291.3K
37KINIKSA PHARMACEUTICALS LTDCOM0.32%$422,40030.0K
38XENEXENON PHARMACEUTICALS INCCOM0.29%$385,00010.0K
39ARVNARVINAS INCCOM0.28%$372,30015.0K
40AXGNAXOGEN INCCOM0.27%$365,20040.0K
41HALOHALOZYME THERAPEUTICS INCCOM0.27%$360,70010.0K
424XC1KALVISTA PHARMACEUTICALS INCCOM0.27%$360,00040.0K
43PGNYPROGYNY INCCOM0.27%$354,0609.0K
44AM6AMICUS THERAPEUTICS INCCOM0.26%$351,68028.0K
45XNCRXENCOR INCCOM0.23%$307,13112.3K
46SRPTSAREPTA THERAPEUTICS INCCOM0.21%$286,3002.5K
47KROSKEROS THERAPEUTICS INCCOM0.21%$281,2607.0K
48CGEMCULLINAN ONCOLOGY INCCOM0.20%$270,22725.1K
49INFLARX NVCOM0.17%$223,00050.0K
50BCRXBIOCRYST PHARMACEUTICALS INCCOM0.11%$140,80020.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.